Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review)
Cristina Andreea Adam, Răzvan Anghel, Dragoș Traian Marius Marcu, et al.
Life (2022) Vol. 12, Iss. 6, pp. 803-803
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 10
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
Mahmoud E. Youssef, Galal Yahya, Mihaela Simona Popoviciu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6039-6039
Open Access | Times Cited: 40
Arterial Stiffness and its Impact on Cardiovascular Health
Rachel Anne Xuereb, Caroline Jane Magri, Robert G. Xuereb
Current Cardiology Reports (2023) Vol. 25, Iss. 10, pp. 1337-1349
Closed Access | Times Cited: 25
SGLT2 inhibition ameliorates nano plastics-induced premature endothelial senescence and dysfunction
Bikalpa Dhakal, Saugat Shiwakoti, Eun‐Young Park, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 24
Comparative effects of glucose-lowering agents on endothelial function and arterial stiffness in patients with type 2 diabetes: A network meta-analysis
Hayeon Kim, Cheol Ung Choi, Kiyon Rhew, et al.
Atherosclerosis (2024) Vol. 391, pp. 117490-117490
Closed Access | Times Cited: 5
Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Neda Shakour, Shima Karami, Mehrdad Iranshahi, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 18, Iss. 1, pp. 102934-102934
Closed Access | Times Cited: 12
Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes
Francesco Piccirillo, Marina Lanciotti, Annunziata Nusca, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2103-2103
Open Access
The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest
Dimitrios Patoulias, Nikolaos Fragakis, Manfredi Rizzo
Life (2022) Vol. 12, Iss. 12, pp. 2062-2062
Open Access | Times Cited: 15
Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease
Dominika Blachut, Brygida Przywara-Chowaniec, Andrzej Tomasik, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2814-2814
Open Access | Times Cited: 8
Empagliflozin decreases ageing-associated arterial stiffening and vascular fibrosis under normoglycemic conditions
Cédric Neutel, Callan D. Wesley, Melissa Van Praet, et al.
Vascular Pharmacology (2023) Vol. 152, pp. 107212-107212
Open Access | Times Cited: 7
Causes of Chronic Kidney Disease and Their Associations with Cardiovascular Risk and Disease in a Sub-Saharan Low-Income Population
Nkosingiphile Twala, Grace Tade, Patrick H Dessein, et al.
International Journal of Nephrology and Renovascular Disease (2024) Vol. Volume 17, pp. 175-195
Open Access | Times Cited: 2
SGLT2 inhibitors for the treatment of diabetes: a patent review (2019–23)
Rahul Baghel, Nikita Chhikara, Pawan Kumar, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 9, pp. 807-823
Closed Access | Times Cited: 2
SGLT2 Inhibitor: an Emerging Pillar in Heart Failure Therapeutics?
B. Geavlete, Răzvan-Ionuț Popescu, V. Iordache, et al.
MAEDICA – a Journal of Clinical Medicine (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 4
Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review
М. В. Леонова
Consilium Medicum (2024) Vol. 26, Iss. 4, pp. 225-231
Open Access | Times Cited: 1
Is Arterial Stiffness Interconnected with Cardiovascular Drug Prescription Patterns, Body Composition Parameters, and the Quality of Blood Pressure Regulation in Hypertensive Patients?
Josipa Radić, Marijana Vučković, Hana Đogaš, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 2062-2062
Open Access | Times Cited: 1
Translational Science in Vascular Aging: From Bench to Bedside—Insights from a VascAgeNet Roundtable
Elisabetta Bianchini, Lynn Roth, Pierre Boutouyrie, et al.
Artery Research (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 1
Oxidative Stress in Kidney Injury and Hypertension
William J. Arendshorst, Aleksandr E. Vendrov, Nitin Kumar, et al.
Antioxidants (2024) Vol. 13, Iss. 12, pp. 1454-1454
Open Access | Times Cited: 1
Non-Traditional Pro-Inflammatory and Pro-Atherosclerotic Risk Factors Related to Systemic Lupus Erythematosus
Patricia Richter, Anca Cardoneanu, Ciprian Rezuș, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12604-12604
Open Access | Times Cited: 6
Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases
Jaime Sanz‐Cánovas, Michele Ricci, Lidia Cobos-Palacios, et al.
Reviews in Cardiovascular Medicine (2023) Vol. 24, Iss. 2, pp. 36-36
Open Access | Times Cited: 3
Early and Late Stages of Chronic Kidney Disease in Relation to Arterial Changes
Agnė Laučytė-Cibulskienė, Mikael Gottsäter
Elsevier eBooks (2024), pp. 381-392
Closed Access
Management of macrovascular diabetic complications: a single-center case series analysis of consecutively attending patients in primary care
Sanda Maria Crețoiu, Mihaela Adela Iancu, Laura Condur, et al.
Journal of Mind and Medical Sciences (2024) Vol. 11, Iss. 1, pp. 114-122
Open Access
Pharmacological Manipulation of the Aging Pathways to Effect Health Span and Lifespan with Special Reference to SGLT2 Inhibitors as Powerful Anti-aging Agents in Humans
M. K.
Insights in Biology and Medicine (2024) Vol. 8, Iss. 1, pp. 011-025
Open Access
Determinants of Arterial Stiffness in Patients with Morbid Obesity. The Role of Echocardiography and Carotid Ultrasound Imaging
Viviana Aursulesei, C Zamfir, Ecaterina Anisie, et al.
Medicina (2023) Vol. 59, Iss. 3, pp. 428-428
Open Access | Times Cited: 1
Toma de posición. Efecto de los iSGLT-2 sobre la presión arterial, el daño vascular, la enfermedad renal y el riesgo cardiovascular asociado
Felipe Inserra, Ezequiel Forte, Alicia Elbert, et al.
Revista de la Sociedad Argentina de Diabetes (2023) Vol. 57, Iss. 3
Open Access | Times Cited: 1
Effects of sodium-glucose co-transporter-2 inhibitors on anthropometric indices and metabolic markers in overweight/obese individuals without diabetes: a systematic review and meta-analysis
Behnaz Abiri, Amirhossein Ramezani Ahmadi, Amir Ebadinejad, et al.
Current Medical Research and Opinion (2022) Vol. 38, Iss. 11, pp. 1853-1863
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top